

Efficacy of myo-inositol in the treatment of cutaneous of polycystic ovary syndrome

Gynecological Endocrinology

25, 508-513

DOI: [10.1080/09513590903015544](https://doi.org/10.1080/09513590903015544)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The D-chiro-inositol paradox in the ovary. <i>Fertility and Sterility</i> , 2011, 95, 2515-2516.	0.5	109
2	The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2011, 27, 920-924.	0.7	49
3	Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. <i>Gynecological Endocrinology</i> , 2012, 28, 969-973.	0.7	71
4	Acupuncture in Polycystic Ovary Syndrome: Potential and Challenge. , 2013, , 487-515.		1
5	The combined therapy myo-inositol plus d-chiro-inositol, rather than d-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. <i>Archives of Gynecology and Obstetrics</i> , 2013, 288, 1405-1411.	0.8	63
6	A Combined Treatment with Myo-Inositol and Monacolin K Improve the Androgen and Lipid Profiles of Insulin-Resistant PCOS Patients. <i>Journal of Metabolic Syndrome</i> , 2013, 02, .	0.1	4
7	Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 623-631.	1.3	51
8	Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome. <i>Journal of Obstetrics and Gynaecology Research</i> , 2014, 40, 1353-1360.	0.6	27
10	Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. <i>Gynecological Endocrinology</i> , 2014, 30, 438-443.	0.7	53
11	The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1079-1092.	1.0	71
12	PCOS Therapy. , 2015, , 89-137.		3
13	Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in Obstetrics and Gynecology – assisted reproduction technology. <i>Gynecological Endocrinology</i> , 2015, 31, 441-446.	0.7	66
14	Reflections on inositol(s) for PCOS therapy: steps toward success. <i>Gynecological Endocrinology</i> , 2015, 31, 501-505.	0.7	83
15	Metabolic Aspects of PCOS. , 2015, , .		6
16	Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. <i>Gynecological Endocrinology</i> , 2015, 31, 131-135.	0.7	55
17	Inositol Treatment and ART Outcomes in Women with PCOS. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-9.	0.6	25
18	Myo-Inositol Safety in Pregnancy: From Preimplantation Development to Newborn Animals. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-10.	0.6	12
19	Different Effects of Myoinositol plus Folic Acid versus Combined Oral Treatment on Androgen Levels in PCOS Women. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-8.	0.6	25

#	ARTICLE	IF	CITATIONS
20	Physiological role and clinical utility of inositols in polycystic ovary syndrome. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2016, 37, 129-139.	1.4	31
21	Inositol™s and other nutraceuticals™ synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. Gynecological Endocrinology, 2016, 32, 431-438.	0.7	82
22	Inositol and human reproduction. From cellular metabolism to clinical use. Gynecological Endocrinology, 2016, 32, 690-695.	0.7	47
23	Expression of Concern: Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial. Clinical Endocrinology, 2017, 87, 194-200.	1.2	25
24	Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients. Gynecological Endocrinology, 2017, 33, 1-9.	0.7	53
25	A peel-off facial mask comprising myoinositol and trehalose-loaded liposomes improves adult female acne by reducing local hyperandrogenism and activating autophagy. Journal of Cosmetic Dermatology, 2017, 16, 480-484.	0.8	11
26	Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocrine Connections, 2017, 6, 647-658.	0.8	111
27	Pharmacologic Treatment of Polycystic Ovary Syndrome: Alternate and Future Paths. Seminars in Reproductive Medicine, 2017, 35, 326-343.	0.5	4
28	Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. Medicine (United States), 2017, 96, e8842.	0.4	39
29	Study of effect of myoinositol on menstrual irregularities and skin problems in polycystic ovarian syndrome cases. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2017, 6, 2310.	0.0	2
30	Inositols. , 2018, , 213-226.		0
31	Infertility in Women with Polycystic Ovary Syndrome. , 2018, , .		6
32	Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients. Gynecological Endocrinology, 2018, 34, 495-501.	0.7	8
33	The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review. Gynecological Endocrinology, 2018, 34, 545-550.	0.7	38
34	Polycystic Ovary Syndrome in Adolescents: Challenges in Diagnosis and Treatment. International Journal of Endocrinology and Metabolism, 2019, 17, e91554.	0.3	28
35	Effect of Myoinositol and Metformin in combination on clinical and hormonal profile in patients of polycystic ovarian syndrome. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2019, 8, 702.	0.0	4
36	Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial. Gynecological Endocrinology, 2019, 35, 406-411.	0.7	31
38	Efficacy of combination therapy of inositols, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: an observational study. Journal of Obstetrics and Gynaecology, 2020, 40, 96-101.	0.4	24

#	ARTICLE	IF	CITATIONS
39	Inositols in PCOS. <i>Molecules</i> , 2020, 25, 5566.	1.7	49
40	Acne treatments: future trajectories. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 955-961.	0.6	13
41	Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary. <i>International Journal of Endocrinology</i> , 2020, 2020, 1-8.	0.6	20
42	The effect of the combination of myo-inositol and D-chiroinositol in a ratio of 5:1 on the psychoemotional state and manifestations of androgen-dependent dermatopathy in patients with polycystic ovary syndrome. <i>Russian Journal of Human Reproduction</i> , 2021, 27, 97.	0.1	1
43	An oral supplementation based on myo-inositol, folic acid and liposomal magnesium may act synergistically with antibiotic therapy and can improve metabolic profile in patients affected by Hidradenitis suppurativa: our experience. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2021, 155, 749-753.	0.8	2
44	High Doses of D-Chiro-Inositol Alone Induce a PCO-Like Syndrome and Other Alterations in Mouse Ovaries. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5691.	1.8	15
45	The use of inositol stereoisomers for the treatment of patients with clinical and biochemical signs of hyperandrogenism. <i>V F Snegirev Archives of Obstetrics and Gynecology</i> , 2021, 8, .	0.1	0
46	Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies. <i>Reproductive Health</i> , 2021, 18, 13.	1.2	34
47	Obesity and Infertility. , 2014, , 11-31.		2
48	Novel combination for the treatment of acne differentiated based on gender: a new step towards personalized treatment. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2018, 153, 866-871.	0.8	8
49	Myo-inositol: therapeutic possibilities and pregravid preparation in women with pcos. <i>Reproductive Endocrinology</i> , 2018, .	0.0	9
50	Evaluation of the treatment with D-chiroinositol on levels of oxidative stress in pcos patients. <i>Reproductive Endocrinology</i> , 2019, .	0.0	0
51	Inositols in reproductive medicine. <i>Reproductive Endocrinology</i> , 2020, .	0.0	1
52	Inositols and other supplements in the management of PCOS. , 2022, , 167-186.		0
53	POTENTIAL ROLE OF D-CHIRO-INOSITOL IN REDUCING OF OXIDATIVE STRESS IN BLOOD OF NON-OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME. <i>Canadian Journal of Physiology and Pharmacology</i> , 2022, , .	0.7	3
54	Inositols in the ovaries: activities and potential therapeutic applications. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 123-133.	1.5	9
55	A multidisciplinary approach in the management of patients with acne. <i>Reproductive Health of Woman</i> , 2022, , 29-36.	0.0	0
56	Untargeted metabolomics analysis of the plasma metabolic signature of moderate-to-severe acne. <i>Clinica Chimica Acta</i> , 2022, 533, 79-84.	0.5	8

#	ARTICLE	IF	CITATIONS
57	Prospects of exogenous inositols in maintaining of skin, hair and nails condition: A review. <i>Gynecology</i> , 2022, 24, 261-270.	0.1	0
58	Use of myo-inositol in women with polycystic ovary syndrome in the application of auxiliary reproductive technologies. <i>Meditinskiy Sovet</i> , 2022, , 50-56.	0.1	1
59	Efficacy of Myo-inositol in Improving Pregnancy Rate and Regulation of Menstrual Cycle for Patients With Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis. <i>Journal of Medicine University of Santo Tomas</i> , 2022, 6, 979-998.	0.0	1
60	Effects of myo-inositol plus folic acid on ovarian morphology and oocyte quality in PCOS mouse model. <i>Zygote</i> , 0, , 1-12.	0.5	3
61	The "Asthma-Polycystic Ovary Overlap Syndrome" and the Therapeutic Role of Myo-Inositol. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6959.	1.8	3
62	Use of myo-inositol in the treatment of PCOS symptoms in adolescents. , 2023, , 151-165.		0